Actinogen Medical Limited (FRA:3AC)

Market Cap	87.26M +39.4%
Revenue (ttm)	3.06M -44.7%
Net Income	-8.22M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8,432
Open	0.0225
Previous Close	0.0220
Day's Range	0.0225 - 0.0225
52-Week Range	0.0080 - 0.0450
Beta	n/a
RSI	42.36
Earnings Date	Feb 19, 2026

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 6
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3AC

Financial Performance

In fiscal year 2025, Actinogen Medical's revenue was 5.49 million, a decrease of -44.73% compared to the previous year's 9.93 million. Losses were -14.73 million, 12.9% more than in 2024.

Financial numbers in AUD